Rose is an associate editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Timely Initiation of Targeted Therapy for NSCLC Improves Outcomes, Study Finds
June 20th 2023Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.
IMRT for Prostate Cancer Not Associated With Increased Risk of Second Primary Cancers, Study Finds
June 16th 2023There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.
Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC
June 15th 2023A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
June 9th 2023Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting
June 9th 2023An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Cancer
June 9th 2023Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.
More Work Is Needed to Bring Clinical Trials to Underserved Patients, ASCO Panel Says
June 6th 2023While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.
ZUMA-7 Findings Show Earlier Is Better for Axi-Cel Use in R/R LBCL, Says Dr Jason Westin
June 5th 2023Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.
Social Determinants of Health Impact Germline Testing Rates Among Patients With TNBC
June 4th 2023Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Osimertinib Shows Significant OS Benefit in Patients With Resected, EGFRm NSCLC
June 4th 2023Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.
Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer Studies
June 3rd 2023Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Comorbidities Among Patients With COPD Impact Outcomes, Require Further Research
May 24th 2023A symposium at the 2023 American Thoracic Society International Conference highlighted common comorbidities that warrant consideration in patients who present with chronic obstructive pulmonary disease (COPD).
Measuring and Addressing the Environmental Factors That Impact Social Determinants of Health
May 22nd 2023Quantifying social determinants of health and addressing the factors that allow disparities to persist will require standardized measurements and targeted interventions, said a panel of experts at the 2023 American Thoracic Society International Conference.
Dr Mark Socinski on the Importance of Targeted Therapy and Immunotherapy in NSCLC
May 21st 2023Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shared his thoughts on the most important recent advances in non–small cell lung cancer (NSCLC), including a better understanding of patients who may benefit from immunotherapy.
Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation
May 21st 2023In the phase 3 BOREAS study of patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation, patients treated with dupilumab experienced fewer COPD exacerbations, improved lung function, and improved quality of life compared with patients given a placebo.
Treatment Improves Outcomes in Patients With CRSwNP, Features of Obstructive Lung Disease
May 19th 2023In the phase 3 SINUS-24 and SINUS-52 trials, dupilumab improved clinical outcomes and and health-related quality of life among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease.
Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC
May 17th 2023Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)
ATS International Conference to Highlight Key Research and Themes in Respiratory Medicine
May 16th 2023This year’s American Thoracic Society (ATS) International Conference will spotlight not only the latest research in respiratory medicine, but also timely themes such as minority health equity, the effects of climate on health, and reducing gun violence through advocacy.